Theriva Biologics to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
Initial CD388 clinical data expected in the first half of 2023SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics,...
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in...
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
Strengthened relationship with LKCM Headwater prompts a shift in leadership and refocused business strategyWARSAW, Ind., Dec. 01, 2022 (GLOBE NEWSWIRE)...
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease...
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like...
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
The iconic cannabis and lifestyle brand joins Petalfast’s route-through-market sales platform in California and ArizonaIRVINE, Calif., Dec. 01, 2022 (GLOBE...
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine...
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC)...
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for HR+, HER2- advanced breast cancer...
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Hydreight Technologies Inc. has received final approval for its qualifying transaction as principally described in its filing statement dated November...
Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clinical needs and improve patient outcomes...
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New OrleansSAN DIEGO, Dec....
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that...
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product DevelopmentMORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) --...